ArcherDX Blog



May
12
2017

Archer at Immunology 2017

Archer exhibits at the American Association of Immunologists Annual Meeting–Immunology 2017 in Washington, DC. At the largest annual gathering of immunologists worldwide, scientists discuss breakthroughs across the full spectrum of topics in the Immunology.


May
5
2017

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017


May
2
2017

Archer presents workshop at Biomarkers and Immuno-Oncology World Congress 2017

We'll be exhibiting at Cambridge Healthtech Institute’s Thirteenth Annual Biomarkers and Immuno-Oncology World Congress and will presenting a poster and a workshop featuring on B- and T-Cell Immune Repertoire Characterization by Anchored Multiplex PCR and Next-Generation Sequencing. This conference is dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines.


Apr
27
2017

Archer at 106th Annual Meeting of Japanese Society of Pathology in Tokyo

We'll be co-attending with Illumina at the inaugural Japanese Society of Pathology in Tokyo. We'll be presenting five posters at this event and giving away corresponding poster flyers with the lead scientist contact info for later review. This gathering will strive to establish a focus on diagnosis that is based on an integrated understanding of disease through the use of high-sensitivity, high-volume analytical technologies like next-generation sequencers and embrace the ideal of giving something back to medicine and society as the goal of pathology.


Apr
8
2017

Meet us at the Rocky Mountain Blood Cancer Conference

Archer is Denver on April 8th promoting awareness of NGS in blood cancer cancer research at the Rocky Mountain Blood Cancer Conference hosted by the Leukemia and Lymphoma Society. This a free educational conference for patients, survivors, caregivers and healthcare professionals.


Apr
3
2017

ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration (CFDA).


Apr
3
2017

AMP Global 2017

Meet us in Berlin, Germany this April for the inaugural AMP 2017 Global Congress on Molecular Pathology: Diagnostic Technologies and Clinical Applications. A multi-disciplinary scientific program showcases molecular technology with clinical applications in oncology (solid tumors, hematopathology), genetics (congenital, heritable), and infectious diseases.


Mar
4
2017

Archer sponsors Snowshoe for the Cure

Archer partners with Susan G. Komen Colorado for the Snowshoe for the Cure. A truly unique event that combines the community's philanthropic spirit with Coloradans' love for the great outdoors - all in an effort to combat the most frequently diagnosed cancer worldwide. Upwards of 1,500 enthusiastic participants strap on their snowshoes in an effort to stomp out breast cancer, a disease that impacts 1 in every 7 women in Colorado.


Mar
22
2017

Archer at the 2017 ACMG Annual Clinical Genetics Meeting

Meet us in Phoenix, AZ this March for the 2017 ACMG Annual Clinical Genetics Meeting. The ACMG provides genetics professionals with the opportunity to learn how genetics and genomics are being integrated into medical or clinical practice. ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.


Apr
1
2017

AACR Annual Meeting 2017

The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research.


Mar
4
2017

Archer exhibits at USCAP 2017 Annual Meeting

Meet us in San Antonio, TX this March for The USCAP 2017 Annual Meeting. This conference boasts the largest gathering of Pathologists in the world. We will be presenting posters illustrating our latest technologies including detection of mutations in ctDNA and B- and T-cell immune repertoire characterization with Anchored Multiplex PCR and Next-Generation Sequencing.


Jan
31
2017

Festival of Genomics London 2017

Join us at the 2017 Festival of Genomics in London this January. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® is unleashing the power of translational NGS to enable mutation detection.


Feb
19
2017

Archer presents at Molecular Med TRI-CON 2017

Join us at Molecular Med TRI-CON 2017 in San Francisco this February. This conference focuses on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology. Our featured talk will be Improving NGS-Based Liquid Biopsy Mutation Detection with Anchored Multiplex PCR presented by Archer CSO, General Manager, Josh Stahl.


Jan
23
2017

Precision Medicine World Conference 2017

Join us for the Precision Medicine World Conference in Silicon Valley, January 24-27th. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Dec
20
2016

Detecting meaningful mutations from liquid biopsies by Anchored Multiplex PCR

In this webinar, Josh Stahl and Jonathan Doose from ArcherDX will describe AMP-based ctDNA library preparation method, highlighting the use and advantages of molecular barcoded adapters used to unambiguously remove PCR duplicates, correct for PCR or sequencer-derived sequence errors, and flag run-to-run contamination. They will then talk about how the Archer® Reveal ctDNA™ 28 kit uses AMP combines robust variant detection and quantitative analysis with single-day library prep for powerful, accurate and fast mutation analysis from liquid biopsies.


Dec
16
2016

From enhanced variant calling to immune repertoire analysis: Greater assay design and analytics with Archer software updates

In this webinar, Brent Lutz, Product Manager of Software, and Doug Wendel, Senior Director of Software, will detail new Assay Designer and Analysis features designed to leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays. Their talk will cover: • Enhanced variant calling via error correction and multi-sample noise reduction • Immune repertoire analysis • Archer Quiver™ Fusion Database customization • REST API for robust workflow integration • Mix & match cached targets for simple and fast custom assays • Integration with third party reporting providers


Dec
5
2016

ArcherDX launches Immune Repertoire Sequencing Assays at ASH 2016

ArcherDX, the leader in NGS-based fusion assays, today announced the release of the Archer® Immunoverse™ immune repertoire sequencing assays. ArcherDX plans to reveal Immunoverse at the 58th American Society of Hematology Annual Meeting, which starts this weekend in San Diego, CA.


Dec
3
2016

Meet us at ASH 2016

Join us for the 2016 The American Society of Hematology (ASH) in San Diego, CA. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Nov
17
2016

ArcherDx Focuses on CDx and IVD Development Based on Patented Target Capture Tech

ArcherDx has been developing new products for cancer research and other applications over the past year and has established additional partnerships, including for companion diagnostic and in vitro diagnostic development. Last week, the company and its customers presented several posters at the American Molecular Pathology annual meeting on research involving many new assays. In addition, the firm was recently granted a US patent for its core technology, which enables open-ended capture of target sequences from a single primer for next-gen sequencing analysis.


Nov
14
2016

Anchored Multiplex PCR patent is issued to inventors at Massachusetts General Hospital

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today the issuance of the first patent for Anchored Multiplex PCR (AMP™), the technology that forms the foundation of the company’s products.


Nov
9
2016

Meet us at AMP 2016

Join us at the 2016 Association of Molecular Pathology Annual Meeting in Charlotte, North Carolina.


Oct
12
2016

ArcherDX at the Companion Diagnostics Symposium 2016

Join us at the 2016 Companion Diagnostics Symposium in Edison, NJ this November. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® is unleashing the power of translational NGS to enable mutation detection.


Oct
11
2016

Why I work at ArcherDX

Erik Reckase describes his experiences on his journey to Archer, seeking a meaningful work environment where learning and collaboration is encouraged.


Oct
5
2016

Validation of the Archer® FusionPlex® Solid Tumor Panel in the JAX Cancer Treatment Profile™

This webinar outlines the clinical validation of the incorporation of the Archer® FusionPlex® Solid Tumor Panel (AFPSTP) into the JAX Cancer Treatment Profile™ (JAX-CTP) test system


Oct
7
2016

ArcherDX at the 2016 ESMO Congress

Join us at the ESMO Congress in Copenhagen, Denmark on 7-11 October, 2016. Combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® unleashes the power of translational NGS to enable mutation detection.


Sep
15
2016

Clinical Tumor Sequencing: Applications and considerations for targeted sequencing using Anchored Multiplex PCR

This webinar will review multiple applications of AMP-based NGS performed in a global CRO, discussing assay suitability and performance for multiple disease and mutation types


Sep
6
2016

PierianDX and ArcherDX Announce Partnership Benefiting NGS Clinical Labs

PierianDX will integrate Archer® targeted NGS testing pipelines into the PierianDX Clinical Genomicist Workspace™


Sep
25
2016

ArcherDX presents at IAP/ESP 2016 in Cologne, Germany

Join us at the IAP/ESP 2016 International Congress in Cologne, Germany on Sept 25-29, 2016. Combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® unleashes the power of translational NGS to enable mutation detection.


Aug
17
2016

Archer announces Research Challenge Grant Winners

Archer awards 5 recipients up to 192 free reactions (24 kits with 8 reactions each) of an Archer Assay of their choosing and training from our expert Field Applications Specialists.


Aug
16
2016

ArcherDX NGS assays receive conditional approval by New York State

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today that two Archer® FusionPlex® NGS assays have received conditional approval from the New York State Department of Health for clinical use by Memorial Sloan Kettering Cancer Center (MSK).


Sep
22
2016

AGBT-Precision Health 2016

Join us at AGBT Precision Health Meeting in Scottsdale, Arizona on Sept 22-24, 2016 to see how combining Archer® NGS assays with GenomOncology clinical reporting software can enable your precision oncology research


Jul
19
2016

ArcherDX at the Cancer Genomics Consortium 2016

Thanks for joining us at the CGC Summer Meeting 2016 in Denver, Colorado in August. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® is unleashing the power of translational NGS to enable mutation detection.


Jul
19
2016

Characterizing hematologic malignancies with ArcherDX blood cancer assays

This webinar will review multiple applications ArcherDX® FusionPlex® and VariantPlex™ blood cancer assays to address the significant clinical implications in the diagnosis and management of hematologic malignancies.


Jul
9
2016

ArcherDX at EACR24

Going to EACR24? Join ArcherDX for in-booth presentations on ArcherDX’s exciting FusionPlex products and bioinformatics analysis tools. Presentations will be hosted by ArcherDX in booth D470.


May
31
2016

ArcherDX to collaborate with Illumina on NGS-based in vitro diagnostics development

ArcherDX will lead development of diagnostic tests powered by Anchored Multiplex PCR (AMP™) enrichment chemistry that will run on the Illumina® MiSeq® sequencing instrument


Jun
3
2016

ArcherDX at ASCO 2016

Join us at the ASCO Annual Meeting 2016 in Chicago, Illinois from June 3-7, 2016. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer® is unleashing the power of translational NGS to enable mutation detection.


May
12
2016

Developing and validating an ALK, ROS1, RET RNA fusion reference standard for targeted NGS

This webinar will detail the need for accurate and consistent fusion reference standards and how Horizon Discovery and ArcherDX partnered to develop the Archer™ SureShot™ ALK, RET, ROS1 standards.


May
21
2016

European Human Genetics Conference 2016

Join us for the 2016 European Human Genetics Conference in Barcelona, Spain from May 21-24. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Apr
16
2016

Archer announces Research Challenge Grant

Archer will award 5 recipients up to 192 free reactions (24 kits with 8 reactions each) of an Archer Assay of their choosing and training from our expert Field Applications Specialists.


Apr
12
2016

Comprehensive Thyroid and Lung (CTL) kits enable parallel detection of copy number variants and expression levels by next-generation sequencing

CNVs are common oncogenic drivers in lung cancer that result in altered expression profiles. Here, we show that AMP™ enables sensitive NGS-based detection of CNVs and expression profiling of multiple genes relevant to lung cancer.


Apr
16
2016

New Archer Blood Cancer NGS Assays announced at AACR 2016

Join us for AACR 2016 in New Orleans, LA from April 16-20. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Apr
6
2016

Next Generation Sequencing Applications and Sample Prep Workflow Improvements

This webinar will detail the advantages of gene fusion detection via RNA-Seq methods and enhancements that can be gained through improvements in nucleic acid purification protocols.


Apr
6
2016

Anchored Multiplex PCR enables sensitive detection and internal verification of novel gene fusions

Current methods to detect gene fusions in clinical samples, such as FISH and IHC, cannot identify novel fusion partners. AMP-based NGS is a sensitive method to detect both known and unknown gene fusions. In this article, we show that AMP-based NGS detected an EML4-ALK fusion in a sample that was ambiguous by ALK break-apart FISH testing.


Apr
5
2016

Breakpoint identification is more sensitive than expression imbalance to detect gene fusions

Expression imbalance can be used to infer the presence of a gene fusion. However, recent data suggest that breakpoint identification may be a more accurate approach. Here, we show that breakpoint identification is more sensitive than expression imbalance to detect gene fusions by AMP-based NGS.


Apr
3
2016

ArcherDX at the 13th International Congress of Human Genetics (ICHG)

Join us for the International Congress of Human Genetics in Kyoto, Japan from April 3-7, 2016. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Mar
12
2016

New Archer options revealed at USCAP 2016 Annual Meeting

Join us for the USCAP 2016 Annual Meeting in Seattle, WA from March 12-18. By combining revolutionary AMP™ chemistry with an easy workflow and intuitive software, Archer is unleashing the power of translational NGS to enable mutation detection.


Feb
10
2016

ArcherDX target enrichment kits for NGS detect all major types of oncogenic MET aberrations

Deregulation of the receptor tyrosine kinase, MET, is implicated in a variety of human cancers. This article reviews the underlying genetic aberrations that drive MET deregulation, and how each of these can be detected with target enrichment kits provided by ArcherDX, Inc. for use in downstream NGS assays.


Feb
5
2016

Learn How DNA Integrity Affects Detection Sensitivity and What You Can Do to Maximize Sensitivity

FFPE storage of clinical specimens damages DNA, resulting in poor sequencing coverage and lowered sensitivity of variant detection. Read on to find out how to overcome this issue using the Archer PreSeq DNA QC Assay and online genome calculator.


Jan
20
2016

Next-Generation Sequencing is More Accurate Than Fluorescence in Situ Hybridization to Detect Malignancy in Cytologic Specimens

What benefits does addition of NGS or FISH impart on assessment of neoplastic pancreaticobiliary malignancies? This study provides some exciting answers.


Dec
10
2015

Technical Note: Archer Analysis Variant and CNV detection methods

Technical note describing variant and CNV detection methods for Archer Analysis software version 4.0.0.


Dec
10
2015

Technical Note: The use of molecular barcodes in Anchored Multiplex PCR

The advantages of molecular barcodes (MBCs) with Anchored Multiplex PCR chemistry.


Dec
10
2015

Technical Note: Beyond Nanograms - Amplifiable genomes to assess NGS library complexity from FFPE samples

Introduction of the PreSeq DNA QC Assay, a simples qPCR assay that facilitates the quantification of the number of sequenceable copies of input genomic DNA, thereby maximizing information recovery from NGS libraries.


Dec
2
2015

What's new in Archer Analysis 4.0?

See what's new in Archer Analysis 4.0. This update introduces many new features and enhancements, such as fusion visualization, RNA abundance, DNA variant filtering, user management and cloud options.


Dec
1
2015

Technical Note: Comprehensive report on FFPE Extraction Methods

Recommendations for extraction kit-specific conditions for nucleic acid preparation from FFPE that are compatible with FusionPlex and VariantPlex library preparation.


Nov
13
2015

AMP 2015 Poster

Presented results from a NSCLC screen using a pair of targeted NGS panels that permit detection of SNVs, indels, CNVs and rearrangements across oncogenes and tumor suppressors relevant to solid tumors from the 2015 Annual Molecular Pathology Meeting.


Nov
4
2015

Technical Note: PreSeq™ RNA QC Assay predicts high-confidence libraries

PreSeq Cq values exhibit a strong concordance with the number of mean control RNA start sites in a library, and correspondingly, a strong agreement with Archer Analysis QC pass.


Nov
5
2015

Association of Molecular Pathology Annual Meeting 2015

Join us for the annual Association of Molecular Pathology Meeting in Austin, TX. By combining revolutionary Anchored Multiplex PCR chemistry with an easy-to-use workflow and intuitive software, Archer is unleashing the power of translational NGS to enable accurate and scalable mutation detection.


Oct
12
2015

ArcherDX Launches NGS Solution for Comprehensive Lung and Thyroid Tumor Profiling

The Archer™ Comprehensive Thyroid and Lung (CTL) Assay combines two complementary targeted NGS panels to detect gene fusions, point mutations, RNA abundance and copy number variations (CNVs) from FFPE and FNA lung and thyroid cancer samples.


Sep
29
2015

ArcherDX and BioChain to Provide NGS-characterized FFPE Tumor Samples

BioChain will supply ArcherDX with multiple types of tumor FFPE samples, including NSCLC samples, which will be comprehensively screened for oncogenic fusions, copy number variations (CNVs), single nucleotide variants (SNVs) and insertions/deletions (indels) using the Archer VariantPlex™ and FusionPlex™ Solid Tumor assays.


Sep
18
2015

Clinically actionable gene fusions, CNVs and SNVs detected by NGS-based comprehensive tumor profiling

Dr. A. John Iafrate, MD PhD discusses the practical challenges of clinical genotyping and how next-generation sequencing (NGS) and Anchored Multiplex PCR (AMP) technologies address those challenges in the clinic.


Sep
15
2015

Can you trust your gene fusion-negative results?

Orthogonal verification of fusion-negative FFPE samples using Archer FusionPlex assays revealed a rare MEC-specific fusion (CRTC3-MAML2) in NSCLC


Aug
28
2015

Evolution of NGS-based detection of fusions, SNVs and CNVs using Anchored Multiplex PCR

Brian Kudlow, PhD, discusses the challenges of cancer genomics and how Archer technology addresses those challenges in the laboratory. Dr. Kudlow also discuss what Archer technology is moving towards in the future.


Aug
28
2015

Serendipity or preparedness?

By running experiments to change the FusionPlex protocol, a rare fusion known as CRTC3-MAML2, which is typically found in mucoepidermoid carcinomas, was found in all 10 replicates in a lung tumor sample.


Jul
22
2015

When career and passion gracefully collide

Over the past six months of working at Archer, I have become increasingly proud and excited to work for a company whose underlying mission is aligned with mine.


Jul
22
2015

RNA Fusion Sensitivity Analysis

Here we describe a sensitivity experiment we conducted with a custom panel we designed for the detection of gene fusions in the ALK, BDNF, NGF, NGFR, NTF3, NTRK1,2 and 3, RET and ROS1 genes that are often found to be involved in various lung cancers.


Jul
16
2015

Archer Analysis Software Webinar by Thon deBoer

New features discussed include the ability to probe DNA/RNA mutations and enumerate copy number variations, graphical metrics output, and better progress indications


Jun
23
2015

Dr. Kudlow speaks at Festival of Genomics, 2015

Seminar: Comprehensive tumor profiling: a targeted approach using purpose-built technology


May
22
2015

Beyond Fusions - Webinar by Josh Stahl

Josh Stahl, Vice-President of R&D and Scientific Operations at ArcherDX, describes the benefits of AMP chemistry and how it is best suited for DNA-based mutation detection. He will also discuss how Archer VariantPlex assays detect CNVs from DNA, and how combining FusionPlex and VariantPlex assays maximizes mutation detection from a single FFPE sample.


May
20
2015

Archer Analysis updated to version 3.2

Archer Analysis has been updated to version 3.2 to include support for CNV detection via Archer VariantPlex DNA panels and printable analysis reports.


May
29
2015

Meet the next-gen variant detection experts at ASCO 2015

To address the existing bottlenecks of using NGS in translational research, we’ve created a line of innovative products that are purpose-built for clinical oncology research. Learn how Archer™ NGS assays are revolutionizing RNA/DNA analysis.


Mar
10
2015

Identifying translocations in solid tumors: Webinar by Brady Culver, PhD

Brady Culver, PhD, Senior R&D Manager and Lead Scientist at ArcherDX, describes the challenges of gene fusions discovery in solid tumors and his process for developing and characterizing a comprehensive NGS panel to assess translocations in these tumor types.


Feb
25
2015

CNV Detection Poster

Development and validation of a directed, rapid and highly multiplexed assay to detect copy number variations in clinical samples - Poster, AGBT 2015


Feb
25
2015

FusionPlex NGS Analysis Poster

Archer™ FusionPlex™ NGS Data Analysis, Algorithms and Methods: Hypothesis-Free Gene Fusion Detection - Poster from AGBT 2015 Conference


Feb
25
2015

VariantPlex BRCA Panel Poster

Optimization of nested PCR conditions to improve target coverage uniformity in Archer™ VariantPlex™ BRCA Panel - Poster, AGBT 2015


Feb
25
2015

Archer assays are purpose-built for revolutionary mutation calling - Learn more at AGBT, 2015

To address the existing bottlenecks of using NGS in translational research, we’ve created a line of innovative products that are purpose-built for clinical oncology research. Learn how Archer™ NGS assays are revolutionizing RNA/DNA analysis.


Feb
17
2015

Change is not coming. Change is here. See ArcherDX at TriCon 2015

Join us at Molecular Medicine Tri-Conference 2015 to learn about how Archer™ FusionPlex™ Assays are bridging the gap between NGS and scalable, accurate and comprehensive gene fusion detection.


Jan
12
2015

ArcherDX Launches from QIAGEN Acquisition of Enzymatics

ArcherDX enters a strategic partnership with QIAGEN for distribution of targeted next-generation sequencing assays and Jason Myers, Ph.D., becomes Chief Executive Officer of ArcherDX


Dec
10
2014

The Value of Richer NGS Data Sets Using Anchored Multiplex PCR – Webinar by Brian Kudlow, PhD

In this webinar, Dr. Kudlow discussed catalog and custom Archer™ products built upon the AMP™ technology and reviewed the scope and power of the data generated with this technology.


Oct
7
2014

Archer Analysis Pipeline update, version 3.0

The Archer Analysis Pipeline has been updated from version 2.1 to 3.0 to bring greater functionality, faster analysis and more comprehensive reporting.


Jun
13
2014

Archer Analysis Pipeline updates, Version 2.1

Archer Analysis Pipeline version 2.1 updates include improved detection of complex gene fusions, targeted mutation reporting, improved handling of very deeply sequenced samples, and several bug fixes.


Nov
21
2013

AMP for Targeted NGS Poster

Anchored Multiplex PCR for Targeted Next Generation Sequencing - Poster, AMP 2013

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.